Michela Ceccolini

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

Michèle Cavo, Elena Zamagni, Patrizia Tosi et al. · Blood · 2005 · 366 citations

Medicine, Hematology, Oncology +16

A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma

Elena Zamagni, Cristina Nanni, Francesca Patriarca et al. · Haematologica · 2007 · 353 citations · Full text

Medicine, Nuclear Medicine, Radiology +17

Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM).

Michèle Cavo, Francesca Patriarca, Paola Tacchetti et al. · Blood · 2007 · 77 citations

Medicine, Hematology, Pharmacotherapy +14

Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide- Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma

Michèle Cavo, Paola Tacchetti, Francesca Patriarca et al. · Blood · 2008 · 73 citations

Medicine, Hematology, Oncology +12

First‐line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma

Patrizia Tosi, Elena Zamagni, Claudia Cellini et al. · European Journal Of Haematology · 2006 · 54 citations

Medicine, Pharmacology, Pharmacotherapy +17